News
Truist Financial Q2 Earnings Call Highlights
Key Points
- Interested in Truist Financial Corporation? Here are five stocks we like better.
- Truist beat earnings expectations in Q2 2026, with net income of $1.5 billion and EPS of $1.23, up
Palantir's Wild Ride: Inside the Stock Wall Street Can't Agree On
Key Points
- Interested in Palantir Technologies Inc.? Here are five stocks we like better.
- Palantir Technologies continues to post exceptional revenue growth, led by U.S. government and commercial
Bayer Aktie: Hybridweizen-Lizenz mit RAGT bis eine Milliarde
Bayer sichert sich Zugang zu einer der letzten großen Lücken im globalen Ackerbau. Der…
Der Beitrag Bayer Aktie: Hybridweizen-Lizenz mit RAGT bis eine Milliarde erschien zuerst auf kapitalmarktexper
Advanced Drainage Systems Shareholders Approve Board, Auditor and Pay at Annual Meeting
Advanced Drainage Systems (NYSE:WMS) held its annual meeting of stockholders virtually, with shareholders approving all three proposals presented by the company, according to meeting remarks from
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
Key Points
- Interested in Abbott Laboratories? Here are five stocks we like better.
- Abbott Laboratories posted solid Q2 results, with 13% reported growth and 4.8% organic growth, showing Exact
Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study
Key Points
- Interested in Insmed, Inc.? Here are five stocks we like better.
- Insmed said 12-month data from its TPIP open-label extension in pulmonary arterial hypertension showed sustained
Abbott Laboratories Q2 Earnings Call Highlights
Key Points
- Interested in Abbott Laboratories? Here are five stocks we like better.
- Abbott beat expectations in Q2, reporting 4.8% comparable sales growth and adjusted EPS of $1.31. Management
UnitedHealth Group Q2 Earnings Call Highlights
Key Points
- Interested in UnitedHealth Group Incorporated? Here are five stocks we like better.
- UnitedHealth beat Q2 expectations with adjusted EPS of $6.38 on $112 billion in revenue, and it
Premier Foods Q1 Earnings Call Highlights
Key Points
- Interested in Premier Foods plc? Here are five stocks we like better.
- Premier Foods reported first-quarter sales growth of 2.7%, driven by stronger branded performance that offset
MicroVision Pitches ‘Lidar 2.0’ Strategy, Keeps 2026 Revenue Outlook Intact
Key Points
- Interested in Microvision, Inc.? Here are five stocks we like better.
- MicroVision is shifting to “Lidar 2.0”, a strategy focused on proving commercial value rather than just sensor
Elevance Health Q2 Earnings Call Highlights
Key Points
- Interested in Elevance Health, Inc.? Here are five stocks we like better.
- Elevance Health raised its 2026 adjusted EPS outlook after Q2 results beat expectations, now guiding to at
Johnson & Johnson Q2 Earnings Call Highlights
Key Points
- Interested in Johnson & Johnson? Here are five stocks we like better.
- Johnson & Johnson raised its full-year 2026 outlook after reporting a Q2 beat on both revenue and earnings
Evotec Aktie: Hammer nach dem Kurssturz
Evotec hat seine Anleger am Montagabend kalt erwischt. Vorläufige Zahlen zum ersten Halbjahr fielen…
Der Beitrag Evotec Aktie: Hammer nach dem Kurssturz erschien zuerst auf kapitalmarktexperten.de.
Bayer Aktie: 1 Milliarde Euro mit Hybridweizen ab 2040
Bayer setzt auf eine Zukunftstechnologie, deren Früchte erst in fast zwei Jahrzehnten reifen sollen.…
Der Beitrag Bayer Aktie: 1 Milliarde Euro mit Hybridweizen ab 2040 erschien zuerst auf kapitalma
EQS-News: Heidelberg Pharma berichtet über das erste Halbjahr 2026 und positiven Geschäftsverlauf
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
Key Points
- Interested in Syndax Pharmaceuticals, Inc.? Here are five stocks we like better.
- Syndax Pharmaceuticals is broadening its growth plan beyond Revuforj and Niktimvo, highlighting new
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss
Key Points
- Interested in Biogen Inc.? Here are five stocks we like better.
- Biogen says its Phase 2 CELIA study of tau-targeting Alzheimer’s drug diranersen missed the main dose-response
Bayer Aktie: 3 Milliarden von Apollo
Bayer verkauft Anteile, um Schulden abzubauen. Der Markt reagiert mit Zurückhaltung statt Euphorie. Die…
Der Beitrag Bayer Aktie: 3 Milliarden von Apollo erschien zuerst auf kapitalmarktexperten.de.
No Space For Panic: T-Mobile Shrugs Off The Starlink Threat
Key Points
- Interested in T-Mobile US, Inc.? Here are five stocks we like better.
- Market fears that satellite internet from Starlink will disrupt telecoms have unfairly dragged down T-Mobile
Evotec Aktie: Prognose halbiert
Vier Monate nach der letzten Zielsetzung wirft Evotec seine eigene Jahresprognose über den Haufen.…
Der Beitrag Evotec Aktie: Prognose halbiert erschien zuerst auf kapitalmarktexperten.de.
Quelle ka
Evotec Q2 Earnings Call Highlights
Key Points
- Interested in Evotec AG? Here are five stocks we like better.
- Evotec cut its 2026 outlook after preliminary Q2 and first-half results showed weaker-than-expected revenue conversion
AngioDynamics Q4 Earnings Call Highlights
Key Points
- Interested in AngioDynamics, Inc.? Here are five stocks we like better.
- Revenue growth was led by med tech: AngioDynamics reported Q4 revenue up 8% to $86.6 million and full-year
Roche Aktie: cobas HDV-Test gestartet
Hepatitis D gilt als die gefährlichste Form der viralen Leberentzündung. Sie trifft nur Menschen,…
Der Beitrag Roche Aktie: cobas HDV-Test gestartet erschien zuerst auf kapitalmarktexperten.de.
Quel
Sangamo Therapeutics Aktie: Pfizer-Aus im Dezember 2024
Sangamo Therapeutics steht vor der endgültigen Zerschlagung. Das einst wegweisende Biotech-Unternehmen treibt den Verkauf…
Der Beitrag Sangamo Therapeutics Aktie: Pfizer-Aus im Dezember 2024
EQS-News: Formycon und OneSource Specialty Pharma geben strategische Partnerschaft für die Herstellung von Biosimilars bekannt